Successful use of fibrin glue during 2 years of surgery at a university medical center.
A method for producing concentrated fibrinogen, an essential component of fibrin glue, from individually stored, single-donor units of human plasma is reported. The plasma is screened for hepatitis B antigen and HIV-1 virus to reduce the risk of transmission of hepatitis and acquired immunodeficiency syndrome (AIDS). This material is routinely stocked in some operating rooms. It is thus readily available when requested by a surgeon for use in combination with topical bovine thrombin to produce fibrin glue. From April 1985 to March 1987 this material was used by surgeons from eight different surgical specialties on 413 patients with a 91 per cent success rate (376/413). Uses have included sealing vascular suture lines, reinforcing pulmonary and esophageal staple lines, closing dural cerebrospinal fluid leaks, fixing split-thickness skin grafts, reducing lymphatic leakage, and controlling bone bleeding. Additional uses include closure of bronchopleural fistulas by means of the flexible bronchoscope, reduction of perioperative hemorrhage by spraying fibrin glue on the anterior mediastinum during cardiac surgery, and reduction of bleeding during debridement of burn eschars. Careful monitoring and patient follow-up detected no cases of transmission of blood-borne diseases. Only one complication, a local wound infection, has been documented. This material has been an important adjunct for the surgical services and may be safely used at hospitals with local blood bank facilities.
Spotnitz
W D
WD
Department of Surgery, University of Virginia School of Medicine, Charlottesville.
Dalton
M S
MS
Baker
J W
JW
Nolan
S P
SP
D007611:Aprotinin / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D005176:Factor XIII / Q000009:adverse effects / Q000627:therapeutic use*; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D013514:Surgical Procedures, Operative; D013917:Thrombin / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen; D005176:Factor XIII; D007611:Aprotinin; D013917:Thrombin